Gaucher Disease Animal Model Service
Gaucher disease (GD), the most common lysosomal storage disorder, is caused by biallelic mutations in the GBA1 gene, which encodes the lysosomal enzyme glucocerebrosidase (GCase), leading to pathological accumulation of glucosylceramide and glucosylsphingosine, particularly in macrophages. Gaucher disease animal models are essential preclinical tools that faithfully recapitulate key disease features, enabling the study of pathogenesis and the evaluation of new therapeutics. Protheragen offers comprehensive, custom-built Gaucher disease animal model services ranging from tailored model development to full preclinical evaluation, ensuring scientifically robust platforms that support your drug discovery and development objectives.
Overview of Gaucher Disease Animal Models
Gaucher disease (GD) results from deficient activity of the lysosomal enzyme glucocerebrosidase, encoded by the GBA1 gene. Reduced GCase activity leads to the progressive accumulation of glucosylceramide (GlcCer) and glucosylsphingosine (GlcSph) within lysosomes, most conspicuously in cells of the mononuclear phagocyte system, giving rise to characteristic Gaucher cells that infiltrate organs and tissues. Gaucher disease is classified into three subtypes based on neurological involvement: Type 1 (non-neuronopathic), Type 2 (acute neuronopathic, infantile form), and Type 3 (chronic neuronopathic).
Fig.1 Overview of animal models employed for investigating GBA1 mutations linked to Gaucher disease. (Cabasso, O., et al., 2023)
Gaucher disease animal models are genetically or chemically generated organisms, primarily rodents, that replicate the fundamental enzyme deficiency and lipid accumulation pathology of the human disease. These models serve as indispensable platforms for decoding disease mechanisms, studying multisystem disease progression, and providing robust preclinical systems for the rigorous evaluation of potential therapeutics. Developing faithful animal models is vital for validating novel therapeutic modalities, including enzyme replacement therapies (ERT), substrate reduction therapies (SRT), pharmacological chaperones, and gene therapies. Because no single model perfectly mirrors every clinical nuance, utilizing distinct, well-characterized in vivo systems is essential for successfully evaluating tissue-specific drug distribution, blood-brain barrier penetration, and long-term efficacy.
Our Services
Backed by deep expertise in Gaucher disease research and lysosomal disorder modeling, Protheragen provides precisely engineered animal model development services that effectively bridge the critical gap between an early research concept and successful clinical translation. From initial consultation through study completion, our integrated, end-to-end service portfolio encompasses everything from custom model generation to rigorous phenotypic characterization and comprehensive efficacy analyses. We offer a data-driven, highly reliable preclinical platform that is thoughtfully designed to accelerate your therapeutic development pipeline.
Animal Models of Gaucher Disease
Custom development of Gaucher disease animal models is offered to meet specific research and therapeutic evaluation needs. Based on project objectives, either genetically engineered or induced model platforms can be generated, fully characterized, and validated for preclinical studies.
Custom genetically engineered models are developed using precise genome modification strategies to recapitulate patient-relevant GBA1 mutations. These models include constitutive knockouts, conditional alleles, and point mutation knock-ins that faithfully reproduce the enzymatic defect and progressive substrate accumulation seen in human Gaucher disease. Developmental timelines, mutation types, and strain backgrounds are tailored to each program.
- Gba1 knockout model
- Gba1 conditional knockout model
- Gba1 L444P knock-in model
- Gba1 D409V point mutation model
- Gba1 F213I knock-in model
- Other models
Pharmacologically induced Gaucher disease models are generated through administration of specific enzyme inhibitors to rapidly reproduce the biochemical hallmarks of the disease. These induced models provide a highly flexible, time-controlled platform for evaluating therapeutic candidates, particularly when rapid screening or reversible disease induction is desired.
- Conduritol-β-epoxide (CBE)-induced mouse model
- Other models
Mouse Model for Gaucher Disease Research
| Model Name | Modeling Method | Detailed Description |
|---|---|---|
| 4L/PS-NA Transgenic Mouse Model | Transgenic / Knock-in | In the 4L/PS-NA strain, prosaposin and saposin concentrations are markedly reduced, and β-glucosidase carries a homozygous V394L point mutation. This combination recapitulates Gaucher disease, the most prevalent lysosomal storage disorder. |
| Gba-KO Mouse Model | Knockout | Exons 8-11 of the Gba gene are deleted, generating a constitutive Gba knockout mouse model. |
| Gba-Flox Mouse Model | Conditional Knockout | LoxP sequences are inserted to flank exons 8 through 11 of the Gba locus. Upon breeding with a line expressing Cre recombinase, these animals enable conditional, tissue-restricted deletion of Gba expression. |
| GBA D409V KI Mouse Model | Knock-in | The GBA D409V knock-in mouse line carries the D409V substitution introduced into exon 10 of the endogenous murine Gba gene, mirroring the same mutation found in the mature human GBA protein that underlies Gaucher disease. |
| CBE-Induced Mouse Model | Chemical Induction | Repeated intraperitoneal administration of conduritol-β-epoxide (CBE) induces GCase deficiency and subsequent accumulation of glucosylceramide and glucosylsphingosine, recapitulating key neuroinflammatory and visceral pathologies of Gaucher disease without genetic modification. |
| … | … | … |
Case Study-CBE-Induced Mouse Model Development
Model Introduction
The conduritol-β-epoxide (CBE)-induced mouse model is a pharmacologically triggered, non-genetic platform for Gaucher disease that recapitulates key neuroinflammatory features of the neuronopathic forms of the disorder. Administration of CBE, a highly specific, irreversible inhibitor of glucocerebrosidase, leads to rapid reduction of enzyme activity, subsequent accumulation of glucosylceramide and glucosylsphingosine, and the hallmark cellular pathology seen in human Gaucher disease. This model is particularly valuable for evaluating central nervous system (CNS) pathology and testing therapies targeting neuroinflammation.
Methodology
- Animal Model: C57BL/6 mice were administered CBE via intraperitoneal injection once daily for nine consecutive days. No genetic modifications were introduced. After the final injection, brain tissues were collected for subsequent histological and immunofluorescent analyses. Control animals received vehicle injections under an identical schedule.
- Phenotypic Analysis Methods: Immunofluorescent labeling was performed on brain sections to detect astrocytosis and microgliosis. Astrocytes were visualized using an antibody against glial fibrillary acidic protein (GFAP), while microglia were identified with an antibody against CD11b. Fluorescent signals were captured under standardized imaging conditions, and the immunoreactive area was quantified using rater-independent, automated image analysis software to ensure objective measurement of signal distribution and intensity.
Phenotypic Analysis & Results
Quantitative analysis of immunofluorescent signals revealed markedly increased neuroinflammatory responses in CBE-treated mice compared to vehicle controls. The immunoreactive area for GFAP, a marker of astrocytosis, was highly elevated in multiple brain regions of treated animals, indicating robust reactive astrogliosis. Similarly, the immunoreactive area for CD11b, a marker of activated microglia, showed a substantial increase in CBE-treated mice, consistent with pronounced microglial activation. These findings confirm that repeated systemic CBE administration reliably induces a strong, reproducible neuroinflammatory phenotype resembling key CNS pathology observed in neuronopathic Gaucher disease.
Fig.2 Neuroinflammatory markers in CBE-treated mouse brain. Quantification of immunoreactive area expressed as percent for CD11b (A) and GFAP (B) in the cortex of vehicle control versus CBE-induced mice. Data are presented as mean ± SEM (n=5; ***p < 0.001, **p < 0.01).
Conclusion
These results demonstrate that a nine-day intraperitoneal CBE dosing regimen in C57BL/6 mice successfully induces robust astrocytosis and microglial activation, two core neuroinflammatory features of neuronopathic Gaucher disease. The quantified increases in GFAP and CD11b immunoreactive areas provide objective, reproducible endpoints suitable for evaluating candidate therapeutics aimed at modulating CNS inflammation. The CBE-induced model thus serves as a practical and time-efficient platform for neuroinflammatory drug discovery and mechanism-of-action studies.
Contact Us
In addition to providing custom Gaucher disease animal models, Protheragen offers a full spectrum of preclinical study services to support your drug development programs. These include pharmacokinetic studies to characterize absorption, distribution, metabolism, and excretion profiles, as well as drug safety evaluation services including general toxicology studies, safety pharmacology assessments, and toxicology studies. Our team works closely with clients to design and execute studies tailored to specific therapeutic modalities, including small molecules, biologics, gene therapies, and enzyme replacement strategies. For inquiries or to discuss your specific project requirements, please contact us. We look forward to partnering with you to advance therapeutics for Gaucher disease.
References
- Cabasso, Or et al. "Animal Models for the Study of Gaucher Disease." International journal of molecular sciences 24.22 (2023): 16035.
- Wen, Shuxia et al. "A novel mouse model of chronic neuronopathic Gaucher disease exhibits Parkinson's disease-like phenotypes." Neurobiology of disease 209 (2025): 106899.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.